Why Is Apogee (APOG) Stock Rocketing Higher Today
While the company faced headwinds from tariffs and lower volumes in its architectural glass segment, CEO Ty R. Silberhorn expressed confidence in a stronger second-half performance. The positive guidance suggests that Apogee's strategic initiatives, including the UW Solutions integration and other investments, are expected to expand its market reach and drive future growth.
Is now the time to buy Apogee? Access our full analysis report here, it's free.
Apogee's shares are somewhat volatile and have had 11 moves greater than 5% over the last year. But moves this big are rare even for Apogee and indicate this news significantly impacted the market's perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock dropped 17% on the news that the company reported underwhelming calendar fourth-quarter 2024 results. Sales were flat year on year, and this weighed on profits as operating margin fell. In addition, its full-year EPS guidance slightly missed, suggesting the weakness might be more pronounced in the coming quarters. Overall, we think this was a challenging quarter.
Apogee is down 41.1% since the beginning of the year, and at $41.88 per share, it is trading 52% below its 52-week high of $87.22 from November 2024. Investors who bought $1,000 worth of Apogee's shares 5 years ago would now be looking at an investment worth $1,780.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook
Aug 1 - First Solar (NASDAQ:FSLR) gained 6.5% on Friday afternoon after posting second?quarter results that topped Wall Street expectations and prompted the solar manufacturer to raise its full?year guidance. Warning! GuruFocus has detected 5 Warning Signs with FSLR. The company reported Q2 net income of $341.9 million, or $3.18 per share, compared with $349.4 million, or $3.25 per share, a year ago. Analysts surveyed by FactSet expected $2.66 per share. Revenue climbed to $1.1 billion from $1.01 billion a year earlier, driven by higher sales of solar modules to third?party customers. Management now projects 2025 revenue between $4.9 billion and $5.7 billion, up from a prior $4.5 billion to $5.5 billion. Earnings guidance tightened to $13.50$16.50 per share, versus the earlier $12.50$17.50 range. First Solar also raised the lower end of its full?year solar module shipment target to 16.719.3 GW and adjusted its gross margin outlook to $2.05$2.35 billion. CEO Mark Widmar said the company benefits from President Trump's recently enacted tax law, which favors U.S.?made solar panels while limiting credits tied to Chinese supply chains. Analysts note that ongoing trade and tariff uncertainty still poses challenges but may also create opportunities for domestic manufacturers. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20 minutes ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
